Clinical Trial Update: Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for stereotactic intracerebral injection of allogenic IPSC-derived dopamine precursor cells in Parkinson disease; recruitment has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IPSC-DAPs (allogenic) (induced pluripotent stem cell-derived dopamine precursor cells)

Snippet

Sponsor: iCamuno Biotherapeutics Ltd. | Conditions: Parkinson Disease | Phase 1 | Status: NOT_YET_RECRUITING